RecruitingPhase 1NCT07425899

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

A Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of ABBV-722 and Upadacitinib Following Multiple Oral Doses in Healthy Adult Subjects

Sponsor

AbbVie

Enrollment

32 participants

Start Date

Feb 26, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteer

Summary

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria2

Laboratory values meet the criteria specified in the protocol.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).

Exclusion Criteria7

History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Chronic recurring infection and/or active viral infection.
Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study drug administration.
Use of tobacco or nicotine-containing products within 90 days prior to the first dose of study drug.
Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
History or evidence of active tuberculosis (TB) disease or latent TB infection
Prior exposure to ABBV-722 within 90 days prior to the first dose of study drug.